7 results on '"Nishimura, E."'
Search Results
2. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
- Author
-
Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, and Nakagawa T
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Humans, Neoplasm Recurrence, Local pathology, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck etiology, Cetuximab adverse effects, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms etiology, Immune Checkpoint Inhibitors, Paclitaxel adverse effects
- Abstract
Objectives: The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration., Materials and Methods: We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45)., Results: The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B., Conclusion: Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
3. A novel cyclic peptide (Naturido) modulates glia-neuron interactions in vitro and reverses ageing-related deficits in senescence-accelerated mice.
- Author
-
Ishiguro S, Shinada T, Wu Z, Karimazawa M, Uchidate M, Nishimura E, Yasuno Y, Ebata M, Sillapakong P, Ishiguro H, Ebata N, Ni J, Jiang M, Goryo M, Otsu K, Harada H, and Suzuki K
- Subjects
- Acetylcholinesterase chemistry, Acetylcholinesterase metabolism, Animals, Astrocytes cytology, Astrocytes metabolism, Axons drug effects, Axons physiology, Cell Proliferation drug effects, Dendrites drug effects, Dendrites physiology, Female, Humans, Hypocreales metabolism, Male, Maze Learning drug effects, Mice, Mice, Inbred C57BL, Mice, Inbred ICR, Microglia cytology, Microglia metabolism, Neurons cytology, Neurons metabolism, Peptides, Cyclic administration & dosage, Peptides, Cyclic chemistry, Peptides, Cyclic isolation & purification, Transforming Growth Factor beta genetics, Transforming Growth Factor beta metabolism, Up-Regulation drug effects, Aging drug effects, Microglia drug effects, Neurons drug effects, Peptides, Cyclic pharmacology
- Abstract
The use of agents that target both glia and neurons may represent a new strategy for the treatment of ageing disorders. Here, we confirmed the presence of the novel cyclic peptide Naturido that originates from a medicinal fungus (Isaria japonica) grown on domestic silkworm (Bombyx mori). We found that Naturido significantly enhanced astrocyte proliferation and activated the single copy gene encoding the neuropeptide VGF and the neuron-derived NGF gene. The addition of the peptide to the culture medium of primary hippocampal neurons increased dendrite length, dendrite number and axon length. Furthermore, the addition of the peptide to primary microglial cultures shifted CGA-activated microglia towards anti-inflammatory and neuroprotective phenotypes. These findings of in vitro glia-neuron interactions led us to evaluate the effects of oral administration of the peptide on brain function and hair ageing in senescence-accelerated mice (SAMP8). In vivo analyses revealed that spatial learning ability and hair quality were improved in Naturido-treated mice compared with untreated mice, to the same level observed in the normal ageing control (SAMR1). These data suggest that Naturido may be a promising glia-neuron modulator for the treatment of not only senescence, but also Alzheimer's disease and other neurodegenerative diseases., Competing Interests: The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: KS, SI, MK, ME, PS, HI and NE are paid employees of DKS Co., Ltd. (the parent company of Biococoon Laboratories, Inc.). This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no products in development or marketing products to declare. Biococoon Laboratories, Inc. and Lotte Co., LTD. have patents and those pending that are related to this study: JP/6182274, US/10654890, EP.FR.GB/3199541, DE/602015044038.2, TW/1683822, CN/201580051652.0 and KR/20177011000. Biococoon Laboratories, Inc. has patents pending that are related to this study: JP/2020-026373, CN/202010493307.5, KR/10-2020-0060224, JP/2020-038183 and JP/2020-183689
- Published
- 2021
- Full Text
- View/download PDF
4. Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo.
- Author
-
Wittchen ES, Nishimura E, McCloskey M, Wang H, Quilliam LA, Chrzanowska-Wodnicka M, and Hartnett ME
- Subjects
- Animals, Choroidal Neovascularization genetics, Cyclic AMP metabolism, Cyclic AMP pharmacology, Disease Models, Animal, Endothelial Cells metabolism, Enzyme Activation, Humans, Intercellular Junctions metabolism, Macular Degeneration genetics, Mice, Mice, Knockout, Transendothelial and Transepithelial Migration drug effects, rap1 GTP-Binding Proteins genetics, Blood-Retinal Barrier metabolism, Choroidal Neovascularization metabolism, Macular Degeneration metabolism, Macular Degeneration pathology, rap1 GTP-Binding Proteins metabolism
- Abstract
Loss of barrier integrity precedes the development of pathologies such as metastasis, inflammatory disorders, and blood-retinal barrier breakdown present in neovascular age-related macular degeneration. Rap1 GTPase is involved in regulating both endothelial and epithelial cell junctions; the specific role of Rap1A vs. Rap1B isoforms is less clear. Compromise of retinal pigment epithelium barrier function is a contributing factor to the development of AMD. We utilized shRNA of Rap1 isoforms in cultured human retinal pigment epithelial cells, along with knockout mouse models to test the role of Rap1 on promoting RPE barrier properties, with emphasis on the dynamic junctional regulation that is triggered when the adhesion between cells is challenged. In vitro, Rap1A shRNA reduced steady-state barrier integrity, whereas Rap1B shRNA affected dynamic junctional responses. In a laser-induced choroidal neovascularization (CNV) model of macular degeneration, Rap1b(-/-) mice exhibited larger CNV volumes compared to wild-type or Rap1a(-/-) . In vivo, intravitreal injection of a cAMP analog (8CPT-2'-O-Me-cAMP) that is a known Rap1 activator significantly reduced laser-induced CNV volume, which correlated with the inhibition of CEC transmigration across 8CPT-2'O-Me-cAMP-treated RPE monolayers in vitro. Rap1 activation by 8CPT-2'-O-Me-cAMP treatment increased recruitment of junctional proteins and F-actin to cell-cell contacts, increasing both the linearity of junctions in vitro and in cells surrounding laser-induced lesions in vivo. We conclude that in vitro, Rap1A may be important for steady state barrier integrity, while Rap1B is involved more in dynamic junctional responses such as resistance to junctional disassembly induced by EGTA and reassembly of cell junctions following disruption. Furthermore, activation of Rap1 in vivo inhibited development of choroidal neovascular lesions in a laser-injury model. Our data suggest that targeting Rap1 isoforms in vivo with 8CPT-2'-O-Me-cAMP may be a viable pharmacological means to strengthen the RPE barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration.
- Published
- 2013
- Full Text
- View/download PDF
5. Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues.
- Author
-
Glendorf T, Knudsen L, Stidsen CE, Hansen BF, Hegelund AC, Sørensen AR, Nishimura E, and Kjeldsen T
- Subjects
- Amino Acid Substitution, Animals, Antigens, CD chemistry, Biochemistry methods, Cell Line, Cricetinae, DNA chemistry, Humans, Inhibitory Concentration 50, Protein Binding, Protein Conformation, Protein Isoforms, Rats, Receptor, IGF Type 1 chemistry, Receptor, Insulin chemistry, Receptor, Insulin metabolism, Saccharomyces cerevisiae metabolism, Insulin analogs & derivatives, Insulin chemistry
- Abstract
Background: Insulin analogues comprising acidic amino acid substitutions at position B10 have previously been shown to display increased mitogenic potencies compared to human insulin and the underlying molecular mechanisms have been subject to much scrutiny and debate. However, B10 is still an attractive position for amino acid substitutions given its important role in hexamer formation. The aim of this study was to investigate the relationships between the receptor binding properties as well as the metabolic and mitogenic potencies of a series of insulin analogues with different amino acid substitutions at position B10 and to identify a B10-substituted insulin analogue without an increased mitogenic to metabolic potency ratio., Methodology/principal Findings: A panel of ten singly-substituted B10 insulin analogues with different amino acid side chain characteristics were prepared and insulin receptor (both isoforms) and IGF-I receptor binding affinities using purified receptors, insulin receptor dissociation rates using BHK cells over-expressing the human insulin receptor, metabolic potencies by lipogenesis in isolated rat adipocytes, and mitogenic potencies using two different cell types predominantly expressing either the insulin or the IGF-I receptor were systematically investigated. Only analogues B10D and B10E with significantly increased insulin and IGF-I receptor affinities as well as decreased insulin receptor dissociation rates displayed enhanced mitogenic potencies in both cell types employed. For the remaining analogues with less pronounced changes in receptor affinities and insulin receptor dissociation rates, no apparent correlation between insulin receptor occupancy time and mitogenicity was observed., Conclusions/significance: Several B10-substituted insulin analogues devoid of disproportionate increases in mitogenic compared to metabolic potencies were identified. In the present study, receptor binding affinity rather than insulin receptor off-rate appears to be the major determinant of both metabolic and mitogenic potency. Our results also suggest that the increased mitogenic potency is attributable to both insulin and IGF-I receptor activation.
- Published
- 2012
- Full Text
- View/download PDF
6. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism.
- Author
-
Galbo T, Olsen GS, Quistorff B, and Nishimura E
- Subjects
- Animals, Cells, Cultured, Insulin Resistance, Lipogenesis, Muscles metabolism, Palmitic Acid pharmacology, Protein Phosphatase 2 genetics, RNA, Messenger analysis, Rats, Rats, Zucker, Fatty Acids, Nonesterified pharmacology, Glucose metabolism, Insulin pharmacology, Liver metabolism, Protein Phosphatase 2 metabolism
- Abstract
In type 2 Diabetes (T2D) free fatty acids (FFAs) in plasma are increased and hepatic insulin resistance is "selective", in the sense that the insulin-mediated decrease of glucose production is blunted while insulin's effect on stimulating lipogenesis is maintained. We investigated the molecular mechanisms underlying this pathogenic paradox. Primary rat hepatocytes were exposed to palmitate for twenty hours. To establish the physiological relevance of the in vitro findings, we also studied insulin-resistant Zucker Diabetic Fatty (ZDF) rats. While insulin-receptor phosphorylation was unaffected, activation of Akt and inactivation of the downstream targets Glycogen synthase kinase 3α (Gsk3α and Forkhead box O1 (FoxO1) was inhibited in palmitate-exposed cells. Accordingly, dose-response curves for insulin-mediated suppression of the FoxO1-induced gluconeogenic genes and for de novo glucose production were right shifted, and insulin-stimulated glucose oxidation and glycogen synthesis were impaired. In contrast, similar to findings in human T2D, the ability of insulin to induce triglyceride (TG) accumulation and transcription of the enzymes that catalyze de novo lipogenesis and TG assembly was unaffected. Insulin-induction of these genes could, however, be blocked by inhibition of the atypical PKCs (aPKCs). The activity of the Akt-inactivating Protein Phosphatase 2A (PP2A) was increased in the insulin-resistant cells. Furthermore, inhibition of PP2A by specific inhibitors increased insulin-stimulated activation of Akt and phosphorylation of FoxO1 and Gsk3α. Finally, PP2A mRNA levels were increased in liver, muscle and adipose tissue, while PP2A activity was increased in liver and muscle tissue in insulin-resistant ZDF rats. In conclusion, our findings indicate that FFAs may cause a selective impairment of insulin action upon hepatic glucose metabolism by increasing PP2A activity.
- Published
- 2011
- Full Text
- View/download PDF
7. Engineering of insulin receptor isoform-selective insulin analogues.
- Author
-
Glendorf T, Stidsen CE, Norrman M, Nishimura E, Sørensen AR, and Kjeldsen T
- Subjects
- Crystallography, X-Ray, Humans, Insulin analogs & derivatives, Mutagenesis, Protein Conformation, Protein Isoforms chemistry, Receptor, Insulin chemistry, Receptor, Insulin genetics, Insulin metabolism, Protein Engineering, Protein Isoforms metabolism, Receptor, Insulin metabolism
- Abstract
Background: The insulin receptor (IR) exists in two isoforms, A and B, and the isoform expression pattern is tissue-specific. The C-terminus of the insulin B chain is important for receptor binding and has been shown to contact the IR just adjacent to the region where the A and B isoforms differ. The aim of this study was to investigate the importance of the C-terminus of the B chain in IR isoform binding in order to explore the possibility of engineering tissue-specific/liver-specific insulin analogues., Methodology/principal Findings: Insulin analogue libraries were constructed by total amino acid scanning mutagenesis. The relative binding affinities for the A and B isoform of the IR were determined by competition assays using scintillation proximity assay technology. Structural information was obtained by X-ray crystallography. Introduction of B25A or B25N mutations resulted in analogues with a 2-fold preference for the B compared to the A isoform, whereas the opposite was observed with a B25Y substitution. An acidic amino acid residue at position B27 caused an additional 2-fold selective increase in affinity for the receptor B isoform for analogues bearing a B25N mutation. Furthermore, the combination of B25H with either B27D or B27E also resulted in B isoform-preferential analogues (2-fold preference) even though the corresponding single mutation analogues displayed no differences in relative isoform binding affinity., Conclusions/significance: We have discovered a new class of IR isoform-selective insulin analogues with 2-4-fold differences in relative binding affinities for either the A or the B isoform of the IR compared to human insulin. Our results demonstrate that a mutation at position B25 alone or in combination with a mutation at position B27 in the insulin molecule confers IR isoform selectivity. Isoform-preferential analogues may provide new opportunities for developing insulin analogues with improved clinical benefits.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.